BridgeBio: Next Chapter Begins After Attruby Approval
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
GEN8d
Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
BioPharma Dive11d
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
pharmaphorum9d
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
TipRanks on MSN11d
BridgeBio announces FDA approved Attruby for ATTR-CM patients
Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
Hosted on MSN8d
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
FiercePharma8d
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
BioSpace7d
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
GlobalData on MSN9d
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
Business Insider7d
BridgeBio Pharma Receives Buy Rating Following Attruby’s FDA Approval and Strategic Milestones
Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...
BridgeBio Selects PANTHERx® Rare Specialty Pharmacy for Distribution of Attruby™ (acoramidis)
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...